下一代基于抗体的癌症治疗:抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用 Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors PubMed 2026/09/09 发表J Hematol OncolQ1 · IF 47.8(JCR 2025) 靶点:CD19靶点:CD20靶点:BCMA技术:CAR-T技术:双特异性抗体急性淋巴细胞白血病多发性骨髓瘤B细胞淋巴瘤
CAR-T 疗法治疗中枢神经系统肿瘤的进展 Advances in CAR-T therapy for central nervous system tumors. PubMed 2024/11/06 发表Biomark ResQ1 · IF 14.6(JCR 2025) 靶点:CD19靶点:GD2靶点:HER2技术:CAR-T弥漫大B细胞淋巴瘤急性淋巴细胞白血病淋巴瘤
CD19-抗 ErbB2 scFv 衔接蛋白使 CD19 特异性 CAR-T 细胞根除 ErbB2(+) 实体瘤 A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer. PubMed 2023/01/07 发表CellsQ2 · IF 6(JCR 2025) 靶点:CD19靶点:HER2技术:CAR-T实体瘤淋巴瘤白血病
用嵌合抗原受体工程化人 MAIT 细胞用于肿瘤免疫治疗 Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy. PubMed 2022/09/07 发表J ImmunolQ2 · IF 4(JCR 2025) 靶点:CD19靶点:HER2技术:CAR-T技术:CAR-NK技术:NK 细胞B细胞淋巴瘤乳腺癌淋巴瘤